NCT06284564 2026-04-21
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
M.D. Anderson Cancer Center
CHU de Quebec-Universite Laval